Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1934 1
1941 1
1948 1
1949 1
1951 1
1952 2
1955 1
1962 3
1964 1
1966 1
1969 1
1970 1
1971 7
1972 5
1973 1
1974 3
1975 4
1976 1
1977 3
1978 5
1979 5
1980 3
1981 5
1982 5
1983 7
1984 3
1985 8
1986 12
1987 17
1988 10
1989 14
1990 16
1991 9
1992 11
1993 11
1994 19
1995 17
1996 20
1997 25
1998 25
1999 31
2000 18
2001 29
2002 22
2003 31
2004 45
2005 35
2006 61
2007 58
2008 65
2009 73
2010 81
2011 82
2012 70
2013 89
2014 68
2015 85
2016 105
2017 129
2018 147
2019 146
2020 174
2021 118
Text availability
Article attribute
Article type
Publication date

Search Results

1,858 results
Results by year
Filters applied: . Clear all
Page 1
Pericapsular Nerve Group (PENG) Block for Hip Fracture.
Girón-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Girón-Arango L, et al. Among authors: chin kj. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847. Reg Anesth Pain Med. 2018. PMID: 30063657
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Among authors: chin k. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Among authors: chin k. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
Caries risk assessment.
Gannam CV, Chin KL, Gandhi RP. Gannam CV, et al. Among authors: chin kl. Gen Dent. 2018 Nov-Dec;66(6):12-17. Gen Dent. 2018. PMID: 30444701 Review.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Among authors: chin k. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
1,858 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page